# Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

> **NCT01996839** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 514 (actual)

## Conditions studied

- Inflammation
- Pain
- Cataract

## Interventions

- **DRUG:** Loteprednol Etabonate Gel (BID)
- **DRUG:** Loteprednol Etabonate Gel (TID)
- **DRUG:** Vehicle (BID)
- **DRUG:** Vehicle (TID)

## Key facts

- **NCT ID:** NCT01996839
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-05
- **Final completion:** 2014-07
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01996839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01996839, "Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT01996839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*